Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
Metalloprotease
G-alpha
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Transporter
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
DNA
RNA
Compound
Inorganic ion
Predicted metabolite or user's structure
Reaction
Generic receptor
GPCR
Receptors with enzyme activity
Mitochondria
EPR
Golgi
Nucleus
Lysosome
Peroxisome
Cytoplasm
Extracellular

Normal process
Pathological process
Binding
Cleavage
Covalent modifications
Phosphorylation
Dephosphorylation
Transformation
Transport
Catalysis
Transcription regulation
MicroRNA binding
Competition
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Development A2A receptor signaling


Log In to Post A Comment

Development A2A receptor signaling

Adenosine A2A receptor signaling

Adenosine is a potent biological mediator that affects numerouscell types, including neuronal cells, platelets, neutrophils and smooth muscle cells.Currently, four adenosine receptor subtypes have been identified: A1, A2A, A2B and A3.Adenosine receptors belong to the G-protein-coupled receptor family of cell surfacereceptors. Adenosine A2A receptor is G-protein alpha-s coupled receptorthat induces classical second messenger pathway such as modulation of cAMPproduction.

Adenosine A2A receptor interaction with the trimeric G-proteinalpha-s/ beta/gamma causes the exchange of GDP to GTP bound to G protein alphasubunits and the dissociation of the beta/gamma heterodimers.

Activated G-protein alpha-s stimulates Adenylate cyclase 6 ( Adenylatecyclase type VI ) . Adenylate cyclase type VI increases level of cAMPin cells and activate Protein kinase, cAMP-dependent, regulatory ( PKA-reg(cAMP-dependent) ) that results in Protein kinase, cAMP-dependent, catalytic (PKA-cat (cAMP-dependent) ) activation [1]. In turn, PKA-cat(cAMP-dependent) phosphorylates and stimulates cAMP responsive element bindingprotein 1 ( CREB1 ) [2].

Adenosine A2A receptor facilitates protein secretion through theactivation of PKA-cat (cAMP-dependent) and Phosphoinositide-3-kinase, catalytic (PI3K cat class IA ). Activation of Adenosine A2A receptor transientlyincreases the phosphorylation of Mitogen-activated protein kinase 14 ( P38 MAPK )and Mitogen-activated protein kinases 8-10 ( JNK(MAPK8-10) ), V-akt murine thymomaviral oncogene homolog 1 ( AKT(PKB) ), and Activating transcription factor 2 (ATF-2 ) [3].

Stimulation of Adenosine A2A receptor prevents cells from theapoptosis via PKA-cat (cAMP-dependent) activation [4]. PKA-cat(cAMP-dependent) phosphorylates and activates Rho guanine nucleotide exchange factor(GEF) 7 ( BETA-PIX ) that, in turn, activates Ras-related C3 botulinum toxinsubstrate 1 ( Rac1 ) and Cell division cycle 42 ( Cdc42 ). An effector ofCdc42, Par-6 partitioning defective 6 homolog ( PRAD6 ) interacts withCdc42 in a GTP-dependent manner, and also directly binds to Protein kinase C, zeta( PKC-zeta ), forming a stable ternary complex with Cdc42 andPKC-zeta. This association results in stimulation of PKC-zeta kinaseactivity. PKC-zeta prevents apoptosis via phosphorylation of Ribosomal protein S6kinase, 90kDa ( p90Rsk ), which inhibits BCL2-associated agonist of cell death (BAD ) protein [5]. Stimulation of PKA-cat (cAMP-dependent)enhances nuclear PKC-zeta activity and cell survival [6].

Activation of Cdc42 increases the phosphorylation of P38MAPK and JNK(MAPK8-10) as well as that of ATF-2 and Jun oncogene (c-Jun ) via stimulation Mitogen-activated protein kinase kinase kinase 4 (MEKK4(MAP3K4) )/ Mitogen-activated protein kinase kinase 6 MEK6(MAP2K6)/ P38MAPK and p21 protein (Cdc42/Rac)-activated kinase 1 ( PAK1 )/Mitogen-activated protein kinase kinase kinase 1 ( MEKK1 )/ Mitogen-activatedprotein kinase kinase 7( MEK7(MAP2K7)/ JNK(MAPK8-10) pathways [7].

Activated by cAMP guanine nucleotide exchange factor Rap guaninenucleotide exchange factor (GEF) 2 ( PDZ-GEF1 ) stimulates PI3K cat classIA activation via v-Ha-ras Harvey rat sarcoma viral oncogene homolog ( H-Ras). PI3K cat class IA converts ( PtdIns(4,5)P2 ) to phosphatidylinositol3,4,5-triphosphate ( PtdIns(3,4,5)P3 ) [8].

PtdIns(3,4,5)P3 is a second messenger that directly binds viapleckstrin homology (PH) domen with V-akt murine thymoma viral oncogene homolog 1 (AKT(PKB) ), that activates Conserved helix-loop-helix ubiquitous kinase (IKK-alpha )/ Nuclear factor of kappa light polypeptide gene enhancer in B-cellsinhibitor ( I-kB )/ Nuclear factor of kappa light polypeptide gene enhancer inB-cells ( NF-kB ) signaling [9], [10].

Activation of Adenosine A2a receptor stimulates nitric oxide production inhuman fetal umbilical vein endothelial cells via stimulation of Mitogen-activated proteinkinase 1-3 ( ERK1/2 ) [11]. cAMP binding to Rap guaninenucleotide exchange factor (GEF) 3 ( cAMP-GEFI ) activates transcription of Nitricoxide synthase 3 ( eNOS ) via RAP1A, member of RAS oncogene family ( RAP-1A)/ v-raf murine sarcoma viral oncogene homolog B1 ( B-Raf )/ Mitogen-activatedprotein kinase kinases 1 and 2 ( MEK1(MAP2K1) MEK2(MAP2K2) )/ ERK1/2/ELK1, member of ETS oncogene family ( ELK1 ) pathway [12].